FDA Approves Sanofi and AstraZeneca’s RSV Antibody for Newborns, Infants

On Monday, the FDA announced approval of Sanofi and AstraZeneca’s monoclonal antibody drug Beyfortus (nirsevimab) for the preventative treatment of respiratory syncytial virus in infants entering their first season of RSV, and children up to 24 months old at severe risk of RSV infection entering their second RSV season.